Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882771 | 0.85 | F2R (1.00) | F2RKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL10069461 | 0.85 | F2R (1.00) | F2RKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL882467 | 0.83 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL29766853 | 0.83 | F2R (1.00) | F2RKMT2A | |
| SCHEMBL882810 | 0.82 | F2R (1.00) | F2RKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL10069979 | 0.81 | F2R (0.76) | F2RKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL882468 | 0.81 | F2R (0.85) | F2RKMT2ARAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL10069454 | 0.80 | F2R (0.72) | F2RKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL10069980 | 0.80 | KMT2A (0.73) | F2RKMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL378588 | 0.79 | GAA (0.69) | F2RKMT2ARAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422262-B2 | Compounds and methods for treating diseases mediated by protease activated receptors | THE BROAD INSTITUTE, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2013-12-12 | — | — | US | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040636-A2 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | THE BROAD INSTITUTE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331411-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES MEDIATED BY PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | F2R 1/4885KMT2A 3844/4885RAB9A 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.